Findings

What do systematic reviews say?

7 questions · 7 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 71.4%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%

Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with 5‐aminosalicylic acid (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 3.39 [1.26, 9.13]
3 studies · 311 participants
Very low

Azathioprine or 6‐mercaptopurine vs anti TNF‐ɑ

Serious adverse events · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with anti TNF‐α (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.51 [0.17, 1.54]
1 study · 84 participants
Very low

Azathioprine or 6‐mercaptopurine vs placebo

Serious adverse events · people with surgically‐induced remission in Crohn's disease

Azathioprine or 6‐mercaptopurine showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.78 [0.39, 8.18]
2 studies · 327 participants
Low

Azathioprine or 6‐mercaptopurine vs placebo

Serious adverse events · Patients with active Crohn's disease

Azathioprine or 6‐mercaptopurine showed no clear difference in serious Adverse events compared with placebo (low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 2.57 [0.92, 7.13]
2 studies · 216 participants
Low

Azathioprine or 6‐mercaptopurine vs placebo

Serious adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 2.45 [1.22, 4.9]
4 studies · 556 participants
Very low

Azathioprine or 6‐mercaptopurine vs mesalazine or sulfasalazine

Serious adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with mesalazine or sulfasalazine (very low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 9.37 [1.84, 47.72]
2 studies · 235 participants
Very low

6‐Mercaptopurine vs methotrexate

Serious adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether 6‐Mercaptopurine changes serious adverse events compared with methotrexate (very low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.68 [0.17, 2.75]
1 study · 57 participants
Very low